Diclofenac/hyaluronic acid

Drugs and Aging

Volumn 14, Issue 4, 1999, Pages 313-319

  Peters, Dene C ^a   Foster, Rachel H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HYALURONIC ACID; SUBSTANCE P;

ACTINIC KERATOSIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TOLERABILITY; EPIDERMIS; HUMAN; HUMAN TISSUE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG DELIVERY SYSTEMS; GELS; HUMANS; HYALURONIC ACID;

EID: 0032936756     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914040-00006     Document Type: Review

References (26)

1. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-64
2. Farmer KC, Naylor MF. Sun exposure, sunscreens, and skin cancer prevention: a year-round concern. Ann Pharmacother 1996 Jun; 30: 662-73
3. Marks R, Motley RJ. Skin cancer: recognition and treatment. Drugs 1995; 50: 48-61
4. Noble S, Wagstaff AJ. Tretinoin: a review of its pharmacological properties and clinical efficacy in the topical treatment of photodamaged skin. Drugs Aging 1995; 6: 479-96
5. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacology and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-85
6. Davis R, Yarker YE, Goa KL. Diclofenac/Misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995; 7: 372-93
7. Scott JE. Hyaluronan, multum in parvo. Eur J Rheumatol Inflamm 1995; 15 (1): 3-8
8. Sedlak BJ. Hyal Pharmaceutical looks for home run with HIT drug delivery system. Genetic Engineering News 1995; 15 (15): 16-7
9. Alam CAS, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol 1995; 47: 407-11
10. Hall CL, Yang B, Yang X, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995; 82: 1-20
11. Gustafson S, Wikstrom T, Juhlin L. Histochemical studies of hyaluronan and the hyaluronan receptor ICAM-1 in psoriasis. Int J Tissue React 1995; 17 (4): 167-73
12. McCourt PAG, Ek B, Forsberg N, et al. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994; 269 (48): 30081-4
13. Gustafson S, Bjorkman T, Forsberg N, et al. Accessible hyaluronan receptors identical to ICAM-1 in mouse mast-cell tumours. Glycoconj J 1995; 12: 350-5
14. Glaser V. Cell adhesion-molecular based drugs test the waters in the clinical arena. Genetic Engineering News 1994; 14 (20)
15. Freemantle C, Alam CAS, Brown JR, et al. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Int J Tissue React 1995; 17 (4): 157-66
16. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995; 17 (4): 153-6
17. Papworth J, Colville-Nash P, Alam C, et al. The depletion of substance P by diclofenac in the mouse. Eur J Pharmacol 1997; 325: R1-2
18. Brown MB, Marriott C, Martin GP. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue React 1995; 17 (4): 133-40
19. Bennett FC, Brown MB, Marriott C, et al. The diffusion of diclofenac from hyaluronan and other polysaccharide formulations through human skin in vitro. In: Willoughby DA, editor. Royal Society of Medicine Round Table Series. Vol. 45. London: RSM, 1996: 86-96
20. Lin W, Maibach HI. Percutaneous absorption of diclofenac in hyaluronic acid gel: in vitro study in human skin. In: Willoughby DA, editor. Royal Society of Medicine Round Table Series. Vol. 45. London: RSM, 1996: 167-73
21. Seed MP, Alam CAS, Brown J, et al. The delivery of diclofenac to pathological tissues by hyaluronan (HYAL EX-0001). In: Willoughby DA, editor. Royal Society of Medicine Round Table Series. Vol. 40. London: RSM, 1995: 74-81
22. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-42
23. Kay B. Positive results from pivotal US actinic keratosis trial [news release]. Mississauga, ON: Hyal Pharmaceutical Corlxiration, 1996 Apr 17
24. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997; 38: 187-9
25. Gebauer K, Asculai S. HYAL-CT1101: a novel topical therapy for treatment of superficial basal cell carcinoma [poster presentntation]. 5th World Congress on Cancers of the Skin: Sep 21-23, 1993; Berlin
26. Rose L. Novel topical NSAID shows promise as analgesic [poster presentation]. 7th World Congress on Pain: Aug 22-27, 1993; Paris